{
    "ticker": "ELOX",
    "name": "Eloxx Pharmaceuticals, Inc.",
    "description": "Eloxx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapeutics to treat rare diseases caused by nonsense mutations in genes. Founded in 2015, the company is headquartered in Frisco, Texas, and leverages its proprietary platform to develop RNA-based therapies that enhance protein production in patients with genetic disorders. Eloxx is dedicated to advancing treatments for conditions such as cystic fibrosis, genetic forms of hearing loss, and other genetic diseases where current treatment options are limited or nonexistent. Their lead product candidate, ELX-02, is an investigational therapy designed to restore protein synthesis and is currently being evaluated in clinical trials. The company\u2019s mission is to provide hope and improve the quality of life for patients suffering from rare genetic diseases by pushing the boundaries of genetic medicine. Eloxx is committed to collaboration with academic institutions, healthcare professionals, and patient advocacy groups to drive research and development forward, ensuring that the unique needs of patients are met. The company aims to be at the forefront of transformative therapies that change the landscape of treatment for rare genetic disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Frisco, Texas, USA",
    "founded": "2015",
    "website": "https://www.eloxxpharma.com",
    "ceo": "Sumit Aggarwal",
    "social_media": {
        "twitter": "https://twitter.com/EloxxPharma",
        "linkedin": "https://www.linkedin.com/company/eloxxpharmaceuticals/"
    },
    "investor_relations": "https://www.eloxxpharma.com/investors",
    "key_executives": [
        {
            "name": "Sumit Aggarwal",
            "position": "CEO"
        },
        {
            "name": "Jeffrey A. Dyer",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Development",
            "products": [
                "ELX-02"
            ]
        }
    ],
    "seo": {
        "meta_title": "Eloxx Pharmaceuticals, Inc. | Innovating Genetic Therapies",
        "meta_description": "Eloxx Pharmaceuticals is a biotechnology company dedicated to developing therapies for rare genetic diseases. Explore our innovative pipeline and commitment to patients.",
        "keywords": [
            "Eloxx Pharmaceuticals",
            "Genetic Therapies",
            "Biotechnology",
            "Rare Diseases",
            "ELX-02"
        ]
    },
    "faq": [
        {
            "question": "What is Eloxx Pharmaceuticals known for?",
            "answer": "Eloxx Pharmaceuticals is known for developing innovative therapies for rare genetic diseases caused by nonsense mutations."
        },
        {
            "question": "Who is the CEO of Eloxx Pharmaceuticals?",
            "answer": "Sumit Aggarwal is the CEO of Eloxx Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Eloxx Pharmaceuticals headquartered?",
            "answer": "Eloxx Pharmaceuticals is headquartered in Frisco, Texas, USA."
        },
        {
            "question": "What is Eloxx's lead product candidate?",
            "answer": "Eloxx's lead product candidate is ELX-02, which is being developed for the treatment of cystic fibrosis and other genetic disorders."
        },
        {
            "question": "When was Eloxx Pharmaceuticals founded?",
            "answer": "Eloxx Pharmaceuticals was founded in 2015."
        }
    ],
    "competitors": [
        "PTN",
        "CRIS",
        "EDIT",
        "SGMO"
    ],
    "related_stocks": [
        "AMGN",
        "BIIB",
        "GILD",
        "REGN"
    ]
}